Abbott Laboratories Trading Volume Drops 20 Percent Ranking 90th on May 1 2025

Abbott Laboratories reported a trading volume of $885 million on May 1, 2025, marking a 20.21% decrease from the previous day. The company's trading volume ranked 90th among all stocks traded that day. Abbott's stock price has been on an upward trend, rising 0.10% and marking its fourth consecutive day of gains, with a total increase of 1.58% over the past four days.

Abbott Laboratories has announced that it will be hosting a conference call to discuss its first-quarter earnings results. The call is scheduled for May 4, 2025, at 8:30 AM Eastern Time. During the call, the company's management team will provide an overview of the company's financial performance for the quarter, as well as discuss its outlook for the remainder of the year.

Abbott Laboratories has received approval from the U.S. Food and Drug Administration (FDA) for its new FreeStyle Libre 3 system. The system is a continuous glucose monitoring device that is designed to help people with diabetes manage their blood sugar levels more effectively. The approval is expected to drive sales growth for the company in the coming quarters.

Abbott Laboratories has announced that it will be acquiring Alere, a leading provider of rapid diagnostic tests, for $5.8 billion. The acquisition is expected to expand Abbott's diagnostic capabilities and strengthen its position in the global diagnostics market. The deal is subject to regulatory approval and is expected to close in the second half of 2025.